Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 23, 2014Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease
Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market...
-
Jul 22, 2014Easy to Use Imaging System to Support Planned Intravascular Ultrasound and Fractional Flow Reserve Products
Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the Boston Scientific family of intravascular...
-
Jul 21, 2014Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of...
-
Jul 14, 2014European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely
Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System,...
-
Jul 14, 2014Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease
Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger™...
-
Jul 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results, business highlights and outlook for the second quarter ended June 30, 2014 on Thursday,...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 4, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo 2014 Healthcare Conference on June 17 in Boston, MA. Dan Brennan, executive vice president and chief...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 in Rancho Palos Verdes, CA. David Pierce, senior vice...
-
May 21, 2014Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System continued to demonstrate impressive...
-
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
-
May 15, 2014Boston Scientific Offers World Class Endoscopy Training at its Paris Institute for Advancing ScienceBoston Scientific Reinforces Its Commitment to Global Education and Innovation
Boston Scientific Corporation (NYSE: BSX) celebrated the opening of a new facility dedicated to endoscopy training within its Institute for Advancing Science in Paris. The ceremony included major...
-
May 15, 2014Acquisition Expected to Strengthen Peripheral Interventions Business and Accelerate Growth in Peripheral Atherectomy and Thrombectomy Categories
In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire the...
-
May 10, 2014PREDICt-RM Collaborative Study between Boston Scientific, American College of Cardiology and Yale University Highlights Improved Outcomes in ICD and CRT-D Patients followed with the LATITUDE™ System
Patients using the Boston Scientific Corporation (NYSE: BSX) LATITUDE™ Remote Patient Management system with wireless telemetry demonstrated significantly lower mortality and fewer...
-
May 8, 2014Boston Scientific Shockless Implant Evaluation (SIMPLE) Study Results Presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions
A Boston Scientific Corporation (NYSE: BSX) study demonstrated that outcomes for patients with the company's transvenous implantable cardioverter defibrillators (ICD) who received routine...
-
May 8, 2014Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided sustained and highly...
-
May 6, 2014Innovative Technology Designed to Treat Intrauterine Fibroids and Polyps
Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company. The transaction is expected to close within days. IoGyn has...
-
May 6, 2014Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions
Boston Scientific Corporation (NYSE: BSX) has joined Optum Labs as the Founding Medical Device Partner to help pioneer new research into effective treatments for heart failure and related cardiac...
-
May 5, 2014Broad Set of Data Reinforces Commitment to Advancing Research and Technology in Electrophysiology
Boston Scientific Corporation (NYSE: BSX) will be presenting new data at the 35th Annual Scientific Sessions of the Heart Rhythm Society in San Francisco on May 7-10, highlighting the company's...
-
May 1, 2014Promising Clinical Data to be Presented at Annual Conference
Boston Scientific Corporation (NYSE: BSX) will present select abstracts and clinical data analyses pertaining to key issues in gastroenterology during Digestive Disease Week (DDW®) 2014, May 4-6...
-
May 1, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2014 Healthcare Conference on May 13 in Las Vegas, NV. Susie Lisa, vice president,...
-
May 1, 2014
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
-
Apr 29, 2014Company Exceeds Earnings Per Share Guidance on the Strength of Continued Revenue Growth
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.774 billion during the first quarter ended March 31, 2014. This represents 4 percent operational revenue growth (constant currency...
-
Apr 22, 2014
Boston Scientific Corporation (NYSE: BSX) has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular (LV) pacing leads and RELIANCE™ 4-FRONT...
-
Apr 17, 2014Event Will Be Held in San Francisco, Site of the Heart Rhythm Society 35th Annual Scientific Sessions
Boston Scientific Corporation (NYSE: BSX) will host an investor event on May 8, 2014 to provide an update on company Cardiac Rhythm Management and Electrophysiology initiatives as well as...
-
Apr 15, 2014
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved...
-
Apr 10, 2014Study to Evaluate Clinical Outcomes and Economic Value of the Vercise™ Deep Brain Stimulation (DBS) System
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS)...
-
Apr 7, 2014The first implant of the S-ICD System performed in Hong Kong
Boston Scientific Corporation (NYSE: BSX) has expanded the launch of its S-ICD System into parts of Asia. The first implant of the S-ICD System in Asia was performed in Hong Kong by Prof. Hung Fat...
-
Apr 7, 2014Innovative handle design enables physician preferences for precision, comfort and control when acquiring tissue samples during diagnostic procedures
Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...
-
Apr 1, 2014These and Other Studies Reinforce Global Commitment to the Development of Innovative Therapies to Improve Care for Patients with Cardiovascular Disease
Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...
-
Apr 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...
-
Apr 1, 2014Interim results of the EFFORTLESS registry published in the European Heart Journal
Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...
-
Mar 30, 2014MADIT-CRT Long-Term Follow-up Results Presented at the American College of Cardiology and Published in the New England Journal of Medicine
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE:...
-
Mar 27, 2014Includes Late Breaking Clinical Trial Assessing Use of the Boston Scientific CRT-D Therapyin Patients with Mild Heart Failure
At the 63rd Annual Scientific Session of the American College of Cardiology (ACC), March 29 – 31 in Washington, D.C., Boston Scientific Corporation...
-
Mar 19, 2014
Boston Scientific has received a Shingo award from the Shingo Institute, part of the Jon M. Huntsman School of Business at Utah State University, in...
-
Mar 14, 2014First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance...
Mar 12, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for PatientsContinuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum...
-
Mar 3, 2014
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected Edward J. Ludwig as a Director. The appointment of Mr. Ludwig will...
-
Feb 28, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Healthcare Conference on March 11 in Miami Beach. Dan...
-
Feb 26, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen and Company 34th Annual Healthcare Conference on March 4 in Boston....
-
Feb 24, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two conferences, the 2014 Citi Global Healthcare Conference and the RBC...
-
Feb 14, 2014Fully Covered Metal Stent Provides New Treatment Option for Patients with Refractory Benign Esophageal Strictures
Boston Scientific Corporation (NYSE: BSX) has received CE Mark in Europe for its WallFlex™ Esophageal Fully Covered Stent to treat refractory benign...
Feb 5, 2014System Provides Physicians New Option for Treating Complete Blockages in the Major Arteries of the LegBoston Scientific (NYSE: BSX) has announced the U.S. launch and first use of the OffRoad™ Re-Entry Catheter System, an important addition to the...
-
Feb 4, 2014Fourth Quarter Marks Third Consecutive Quarter of Improved Performance
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.838 billion during the fourth quarter ended December 31, 2013. This represents 5...
-
Feb 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Leerink Swann Global Healthcare Conference on Wednesday, February...
-
Jan 21, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 6, 2014Boston Scientific Names Craig Thompson, M.D. As New Chief Medical Officer, Interventional Cardiology
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Craig Thompson, M.D., as senior vice president and chief medical officer,...
-
Jan 2, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 in